News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biotech Firm Cambridge Antibody Technology Group PLC  (CATG) Sheds Jobs as Owner AstraZeneca PLC (AZN) Submits it to Merger


10/22/2007 12:11:59 AM

One of the best-known names in British biotechnology - Cambridge Antibody Technology (CAT) – is set to disappear this month, amid allegations of broken promises by its parent AstraZeneca. AstraZeneca is merging the company, which it bought for £702 million in 2006, into Medimmune, the much larger American business that it paid more than $15.2 billion for in April this year. It plans to build Medimmune into a standalone subsidiary focused entirely on developing “biologic” drugs – those produced from living material rather than conventional pharmaceuticals.

Read at Deccan Herald

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES